By mediating the correction of mRNA shearing, specifically targeting about 7.7% of splicing variants in the PKHD1 gene, ASO provides a new avenue for the treatment of ARPKD caused by splicing defects. Here, PKHD1 is linked to autosomal recessive polycystic kidney disease.